Clinical Trials Directory
We are doing this study to see how tucatinib, trastuzumab, and mFOLFOX6 work to treat cancer of your colon or rectum that is HER2-positive with mFOLFOX6 alone or combined with bevacizumab.
This study is being done to find out if atropine eyedrops (0.05% atropine, 99.95% inactive solution) and/or special eyeglass lenses are an effective strategy to slow down the progression of myopia for young children with nearsightedness.
We are doing this study to learn more about the differences in the muscle and blood of people that have Peripheral Arterial Disease (PAD).
We are doing this study to compare the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib. We want to find out if adding gilteritinib to the usual treatment is beneficial for people with acute myeloid leukemia (AML).
We are doing this study to find out if 2 different experimental drug combinations can improve outcomes for people who are newly diagnosed with AML. We want to compare the outcomes from the standard treatment (cytarabine + daunorubicin) to the following experimental regimens:
- Venetoclax + cytarabine + daunorubicin
- Venetoclax + azacitidine
We are doing this study to compare different experimental drug regimens to the usual treatment (cytarabine and daunorubicin) for acute myeloid leukemia (AML). We want to find out which options have the best outcomes. The different drug combinations we will be testing against the usual treatment are:
- daunorubicin and cytarabine liposome
- cytarabine and daunorubicin with venetoclax
- azacitidine and venetoclax
- daunorubicin and cytarabine liposome with venetoclax
We are doing this study to see if blood and bone marrow samples can be tested in a timely manner that allows for the detection of certain markers that could guide cancer treatment.
We are doing this study to find out if an investigational vaccine (HydroVax-005 CHIKV - the study vaccine) is a safe and effective option to protect against chikungunya virus. Chikungunya virus is spread by mosquitos that are most common in Africa, Asia, and India. Infection with the virus can cause serious disease in older adults, children, and people with weaker immune systems.